Novartis CCTL019C2201; HM2015-13: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
|Effective start/end date||4/10/15 → 12/14/22|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.